GREGORY CONN - 19 Jan 2022 Form 4 Insider Report for PDS Biotechnology Corp (PDSB)

Role
Chief Scientific Officer
Signature
/s/ Hillary Yegen, attorney-in-fact
Issuer symbol
PDSB
Transactions as of
19 Jan 2022
Net transactions value
$0
Form type
4
Filing time
20 Jan 2022, 15:05:39 UTC
Next filing
06 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PDSB Employee Stock Option (Right to Buy) Award $0 +112,100 $0.000000 112,100 19 Jan 2022 Common Stock 112,100 $6.28 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option, representing a right to purchase a total of 112,100 shares of Common Stock, will become exercisable on January 19, 2023, with 25% vesting on that date and the remaining 75% vesting in equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date, until fully vested on January 19, 2026.